{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:37:14Z","timestamp":1793057834115,"version":"4.5.0"},"reference-count":100,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:p>Homeostasis of the lacrimal functional unit is needed to ensure a well-regulated ocular immune response comprising innate and adaptive phases. When the ocular immune system is excessively stimulated and\/or immunoregulatory mechanisms are disrupted, the balance between innate and adaptive phases is dysregulated and chronic ocular surface inflammation can result, leading to chronic dry eye disease (DED). According to the Tear Film and Ocular Surface Society Dry Eye Workshop II definition, DED is a multifactorial disorder of the ocular surface characterized by impairment and loss of tear homeostasis (hyperosmolarity), ocular discomfort or pain, and neurosensory abnormalities. Dysregulated ocular immune responses result in ocular surface damage, which is a further contributing factor to DED pathology. Several therapeutics are available to break the vicious circle of DED and prevent chronic disease and progression, including immunosuppressive agents (steroids) and immunomodulators (cyclosporine and lifitegrast). Given the chronic inflammatory nature of DED, each of these agents is commonly used in clinical practice. In this study, we review the immunopathology of DED and the molecular and cellular actions of current topical DED therapeutics to inform clinical decision making.<\/jats:p>","DOI":"10.1089\/jop.2019.0060","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T09:47:35Z","timestamp":1584352055000},"page":"137-146","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":166,"title":["The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options"],"prefix":"10.1177","volume":"36","author":[{"given":"Laura M.","family":"Periman","sequence":"first","affiliation":[{"name":"Periman Eye Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Perez","sequence":"additional","affiliation":[{"name":"Duke Eye Center, Duke University School of Medicine, Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Saban","sequence":"additional","affiliation":[{"name":"Duke Eye Center, Duke University School of Medicine, Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng C.","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Optometry, Clinical Research Center, University of California, Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Neri","sequence":"additional","affiliation":[{"name":"The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318225415a"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2003.09.003"},{"issue":"3","key":"e_1_3_4_5_2","first-page":"S102","article-title":"Prevalence, burden, and pharmacoeconomics of dry eye disease","volume":"14","author":"Pflugfelder S.C.","year":"2008","unstructured":"Pflugfelder S.C. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am. J. Manag. Care. 14 Suppl 3:S102\u2013S106, 2008.","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.003"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.12.023"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.9.1264"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076121"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2010.01993.x"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000657"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(11)70034-9"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.11.028"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2015.1088955"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000464"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000356"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23651"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.002"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.011"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.07.010"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000042"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-014-9969-x"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874364101509010049"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(00)00200-9"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101442"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2016.01.001"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036822"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-9299"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020485"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18050978"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2005.08.019"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1145"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401821"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.364"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.8.1132"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2417"},{"key":"e_1_3_4_37_2","first-page":"2609","article-title":"Conjunctival T-cell subpopulations in Sj\u00f6gren's and non-Sj\u00f6gren's patients with dry eye","volume":"43","author":"Stern M.E.","year":"2002","unstructured":"Stern M.E., , Gao J., , Schwalb T.A., , Ngo M., , Tieu D.D., , Chan C.C., , Reis B.L., , Whitcup S.M., , Thompson D., , and Smith J.A. Conjunctival T-cell subpopulations in Sj\u00f6gren's and non-Sj\u00f6gren's patients with dry eye. Invest. Ophthalmol. Vis. Sci. 43:2609\u20132614, 2002.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0069"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.3.330"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2010.26"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2012.02.003"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.04.001"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.004"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.748052"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051759"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300985812469883"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.02.015"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2013.10.007"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-14481"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2013.20"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.08.013"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838535"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2016.0105"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040523"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2007.00537.x"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.3.1247"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332049"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2018.03.008"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2008.04.017"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2009.08.016"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2009.5"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00876"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)33729-3"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00157"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2003.10.024"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.1.531"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802167"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90104-8"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12759"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.3079"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0339-5"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90171-9"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-12660"},{"key":"e_1_3_4_75_2","volume-title":"Allergan","author":"Allergan. Restasis\u00ae (cyclosporine ophthalmic emulsion) 0.05%","year":"2016","unstructured":"Allergan. Restasis\u00ae (cyclosporine ophthalmic emulsion) 0.05%. In: Allergan, ed. Allergan. Irvine, CA: Allergan; 2016."},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00192-2"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.11.1489"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000133994.22392.47"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00749-12"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488411"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)00176-1"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S30261"},{"key":"e_1_3_4_83_2","unstructured":"Luchs J. Phase 3 clinical results of cyclosporine 0.09% in a new nanomicellar ophthalmic solution to treatment keratoconjunctivitis sicca ASCRS-ASOA Annual Meeting. Washington DC; 2018."},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12872"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S126668"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-5078"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0047"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0102"},{"key":"e_1_3_4_89_2","first-page":"2563","article-title":"Inhibition of leukocyte sticking and infiltration, but not rolling, by antibodies to ICAM-1 and LFA-1 in murine endotoxin\u2013induced uveitis","volume":"42","author":"Becker M.D.","year":"2001","unstructured":"Becker M.D., , Garman K., , Whitcup S.M., , Planck S.R., , and Rosenbaum J.T. Inhibition of leukocyte sticking and infiltration, but not rolling, by antibodies to ICAM-1 and LFA-1 in murine endotoxin\u2013induced uveitis. Invest. Ophthalmol. Vis. Sci. 42:2563\u20132566, 2001.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.08.032"},{"key":"e_1_3_4_91_2","first-page":"10","article-title":"Neutrophils cause obstruction of eyelid sebaceous glands in inflammatory eye disease in mice","author":"Reyes N.J.","year":"2018","unstructured":"Reyes N.J., , Yu C., , Mathew R., , Kunnen C.M., , Kalnitsky J., , Redfern R.L., , Leonardi A., , Perez V.L., , MacLeod A.S., , Gupta P.K., , and Saban D.R. Neutrophils cause obstruction of eyelid sebaceous glands in inflammatory eye disease in mice. Sci. Transl. Med. 10, 2018.","journal-title":"Sci. Transl. Med"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.001"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.015"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.025"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000803"},{"key":"e_1_3_4_96_2","first-page":"112067211879193","article-title":"Safety and tolerability of lifitegrast ophthalmic solution 5.0%: pooled analysis of five randomized controlled trials in dry eye disease","author":"Nichols K.K.","year":"2018","unstructured":"Nichols K.K., , Donnenfeld E.D., , Karpecki P.M., , Hovanesian J.A., , Raychaudhuri A., , Shojaei A., , and Zhang S. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: pooled analysis of five randomized controlled trials in dry eye disease. Eur. J. Ophthalmol. 1120672118791936, 2018.","journal-title":"Eur. J. Ophthalmol"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2012-0131"},{"key":"e_1_3_4_98_2","first-page":"877","article-title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAE\u2122) model","volume":"9","author":"Sosne G.","year":"2015","unstructured":"Sosne G., , and Ousler G.W. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAE\u2122) model. Clin. Ophthalmol. 9:877\u2013884, 2015.","journal-title":"Clin. Ophthalmol"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000379"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1019858"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-16890"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2019.0060","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2019.0060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2019.0060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:43:27Z","timestamp":1777646607000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2019.0060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4,1]]}},"alternative-id":["10.1089\/jop.2019.0060"],"URL":"https:\/\/doi.org\/10.1089\/jop.2019.0060","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}